Characteristics and Prognosis of Patients With Hypertensive Encephalopathy: A French Nationwide Cohort Study.


Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
08 2023
Historique:
medline: 21 7 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

Hypertensive encephalopathy (HE) constitutes a serious condition, usually observed in patients with long-lasting hypertension. Hypertension-associated HE is sometimes differentiated from the stroke-associated hypertensive emergency. Whether prognosis of hypertension-associated and stroke-associated HE is different is unclear. Characteristics and prognosis of HE were assessed in this nationwide retrospective cohort study in all patients with an administrative code of HE compared with age-, sex- and year of inclusion-matched controls admitted to French hospitals during the 2014 to 2022 period. HE was identified in 7769 patients. Chronic kidney disease (19.3%), coronary artery disease (13.8%), diabetes (22.1%), and ischemic stroke (5.2%) were frequent but thrombotic microangiopathy, hemolytic-uremic syndrome, systemic sclerosis or renal infarction were <1%. HE prognosis was poor (death: 10.4%/y, heart failure: 8.6%/y, end-stage kidney disease: 9.0%/y, ischemic stroke: 3.6%/y, hemorrhagic stroke: 1.6%/y, dementia: 4.1%/y). The risk of death was increased to a similar extent in patients with HE, regardless of the presence of known hypertension or concomitant stroke (versus patients without HE). Among patients with HE, known hypertension was significantly associated with increased risks of ischemic stroke, hemorrhagic stroke, heart failure, vascular dementia, and all-cause dementia and to a lesser extent with chronic dialysis in multivariable analyses including adjustment on concomitant stroke. HE remains a considerable health burden and is associated with a poor prognosis. The distinction between hypertension- versus stroke-associated HE is relevant as these 2 situations convey different risks of stroke, heart failure, vascular dementia, and end-stage kidney disease.

Sections du résumé

BACKGROUND
Hypertensive encephalopathy (HE) constitutes a serious condition, usually observed in patients with long-lasting hypertension. Hypertension-associated HE is sometimes differentiated from the stroke-associated hypertensive emergency. Whether prognosis of hypertension-associated and stroke-associated HE is different is unclear.
METHODS
Characteristics and prognosis of HE were assessed in this nationwide retrospective cohort study in all patients with an administrative code of HE compared with age-, sex- and year of inclusion-matched controls admitted to French hospitals during the 2014 to 2022 period.
RESULTS
HE was identified in 7769 patients. Chronic kidney disease (19.3%), coronary artery disease (13.8%), diabetes (22.1%), and ischemic stroke (5.2%) were frequent but thrombotic microangiopathy, hemolytic-uremic syndrome, systemic sclerosis or renal infarction were <1%. HE prognosis was poor (death: 10.4%/y, heart failure: 8.6%/y, end-stage kidney disease: 9.0%/y, ischemic stroke: 3.6%/y, hemorrhagic stroke: 1.6%/y, dementia: 4.1%/y). The risk of death was increased to a similar extent in patients with HE, regardless of the presence of known hypertension or concomitant stroke (versus patients without HE). Among patients with HE, known hypertension was significantly associated with increased risks of ischemic stroke, hemorrhagic stroke, heart failure, vascular dementia, and all-cause dementia and to a lesser extent with chronic dialysis in multivariable analyses including adjustment on concomitant stroke.
CONCLUSIONS
HE remains a considerable health burden and is associated with a poor prognosis. The distinction between hypertension- versus stroke-associated HE is relevant as these 2 situations convey different risks of stroke, heart failure, vascular dementia, and end-stage kidney disease.

Identifiants

pubmed: 37283073
doi: 10.1161/HYPERTENSIONAHA.123.21226
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1716-1727

Auteurs

Jean-Michel Halimi (JM)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, France (J.-M.H., J.-P.d.F., P.G., B.S., V.M.).
EA4245, Transplantation Immunologie Inflammation (J.-M.H., P.G., D.A.), Université de Tours, France.
INI-CRCT, France (J.-M.H., B.S.).

Jean-Baptiste de Fréminville (JB)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, France (J.-M.H., J.-P.d.F., P.G., B.S., V.M.).

Philippe Gatault (P)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, France (J.-M.H., J.-P.d.F., P.G., B.S., V.M.).
EA4245, Transplantation Immunologie Inflammation (J.-M.H., P.G., D.A.), Université de Tours, France.

Arnaud Bisson (A)

Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, EA4245 (A.B., P.V., D.A., L.F.), Université de Tours, France.

Bénédicte Sautenet (B)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, France (J.-M.H., J.-P.d.F., P.G., B.S., V.M.).
INI-CRCT, France (J.-M.H., B.S.).
INSERM U1246 SPHERE, Université de Tours-Université de Nantes, France (B.S.).

Valentin Maisons (V)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, France (J.-M.H., J.-P.d.F., P.G., B.S., V.M.).

Pascal Vigny (P)

Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, EA4245 (A.B., P.V., D.A., L.F.), Université de Tours, France.
Service d'Information Médicale, d'Épidémiologie et d'Économie de la Santé, Centre Hospitalier Universitaire et Faculté de Médecine, EA7505 (P.V.), Université de Tours, France.

Denis Angoulvant (D)

EA4245, Transplantation Immunologie Inflammation (J.-M.H., P.G., D.A.), Université de Tours, France.
Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, EA4245 (A.B., P.V., D.A., L.F.), Université de Tours, France.

Laurent Fauchier (L)

Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, EA4245 (A.B., P.V., D.A., L.F.), Université de Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH